Levetiracetam Dosing in Pediatric Patients
For pediatric patients with status epilepticus, use levetiracetam 40-60 mg/kg IV loading dose (maximum 4500 mg) infused over 5-15 minutes, followed by maintenance dosing of 20-60 mg/kg/day divided twice daily, with dose adjustments required for renal impairment.
Loading Dose for Status Epilepticus
The optimal loading dose is 40-60 mg/kg IV based on the most recent high-quality evidence:
- Initial loading: 40 mg/kg IV over 5 minutes is the standard dose validated in the ConSEPT trial 1
- Can use up to 60 mg/kg in refractory cases, though higher doses (>40 mg/kg) may increase intubation risk 2
- Maximum absolute dose: 4500 mg 2
- Infusion time: 5-15 minutes 3
Important Context for Status Epilepticus
While the ConSEPT trial showed levetiracetam was not superior to phenytoin for second-line treatment of pediatric convulsive status epilepticus (50% vs 60% seizure cessation), levetiracetam offers significant practical advantages: faster administration (5 min vs 20 min), better safety profile, and no cardiac monitoring requirements 1. Recent meta-analyses demonstrate levetiracetam reduces time to seizure cessation and ICU length of stay compared to phenytoin 4.
Critical caveat: In neonates, phenobarbital remains first-line (80% efficacy vs 28% for levetiracetam) 5. Levetiracetam should only be considered as second-line in neonatal seizures.
Maintenance Dosing
Standard Maintenance Regimen
Dose: 20-60 mg/kg/day divided twice daily
- Starting dose: 20-30 mg/kg/day in two divided doses 6, 7
- Target maintenance: 40-50 mg/kg/day (up to 3000 mg/day) 8
- Maximum: 60 mg/kg/day 9
Age-Specific Considerations
Children require 30-40% higher weight-normalized doses than adults due to faster clearance 6:
- Infants and children <4 years: Median effective dose 28-30 mg/kg/day 7
- Children 6-12 years: 40-50 mg/kg/day recommended (approximately 130-140% of adult weight-normalized dosing) 6
- Adolescents ≥16 years: Use adult dosing (500-1500 mg twice daily) 3
Dose Titration
Increase by 500 mg (or 10-20 mg/kg) twice daily every 2 weeks until seizure control achieved or maximum dose reached 3.
Renal Impairment Adjustments
Dose reduction is mandatory based on creatinine clearance 3:
- CrCl >80 mL/min: No adjustment needed
- CrCl 50-80 mL/min: Reduce dose by 25%
- CrCl 30-50 mL/min: Reduce dose by 50%
- CrCl <30 mL/min: Reduce dose by 75%
- Dialysis patients: Supplemental dosing post-dialysis required
Calculate pediatric CrCl using Schwartz equation: CrCl = (k × height in cm) / serum creatinine, where k = 0.45 for infants 1-12 months, 0.55 for children/adolescent females, 0.7 for adolescent males.
Administration Guidelines
IV Administration
- Do NOT dilute the premixed levetiracetam in sodium chloride injection 3
- Administer via IV or intraosseous route over 5-15 minutes 3, 1
- Available concentrations: 5 mg/mL (500 mg/100 mL), 10 mg/mL (1000 mg/100 mL), 15 mg/mL (1500 mg/100 mL) 3
Switching Between IV and Oral
Total daily dose and frequency remain identical when switching between formulations 3. Switch to oral as soon as patient can tolerate.
Safety Profile
Levetiracetam is generally well-tolerated in children with significantly fewer adverse effects than phenytoin 1, 4:
Common Adverse Effects (Monitor For):
- Behavioral changes: Agitation, irritability, aggression (3-10% of patients) 10, 7
- Somnolence and fatigue 3
- Leukopenia (rare, monitor CBC) 7
Serious Reactions (Discontinue if occurs):
- DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) 3
- Serious dermatological reactions 3
- Suicidal ideation or psychotic symptoms 3
Discontinuation rate due to adverse effects: <10% in pediatric studies 10, 8, compared to higher rates with phenytoin.
Clinical Pearls
- No cardiac monitoring required (unlike phenytoin/fosphenytoin)
- No drug-drug interactions with other antiepileptics 6
- Faster administration than phenytoin (5 min vs 20 min) improves time to seizure control 4
- Must taper gradually when discontinuing to avoid withdrawal seizures 3
- For refractory partial seizures as adjunctive therapy: Class I evidence supports efficacy at 40 mg/kg/day maximum 9